Page 6 - Algorithm for erectile rehabilitation following prostate cancer treatment

elterman et al

the treatment decision-making process. Instead, they seem to 5. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized
prostate carcinoma. Int J Radiat Oncol Biol Phys 2002;54:1063-8. https://doi.org/10.1016/S0360-
focus on a linear progression of pro-erectile aids, from least 3016(02)03030-4
invasive to most invasive. Ideal clinical management must 6. Haglind E, Carlsson S, Stranne J, et al. Urinary incontinence and erectile dysfunction after robotic vs.
be tailored to patient (and partner) preferences, including open radical prostatectomy: A prospective, controlled, non-randomized trial. Eur Urol 2015;68:216-25.
specific goals for erectile recovery. In addition, considera- https://doi.org/10.1016/j.eururo.2015.02.029
tions from the diverse representation on our multidisciplin- 7. Akbal C, Tinay I, Simsek F, et al. Erectile dysfunction following radiotherapy and brachytherapy for
prostate cancer: Pathophysiology, prevention, and treatment. Int Urol Nephrol 2008;40:355-63.
ary panel highlighted the inclusion of patient experiences https://doi.org/10.1007/s11255-007-9247-1
directly identified by patient advocates, as well as psycho- 8. Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of
social recommendations to enhance patient and partner effi- age: Results from the health professionals followup study. Ann Intern Med 2003;139:161-8.
cacy, acceptance, and compliance with pro-erectile aids. https://doi.org/10.7326/0003-4819-139-3-200308050-00005
Furthermore, sensitivity to the discrepancies in trajectory 9. Nelson CJ, Mulhall JP, Roth AJ. The association between erectile dysfunction and depressive symptoms
in men treated for prostate cancer. J Sex Med 2011;8:560-6. https://doi.org/10.1111/j.1743-
of ED development after RT vs. RP need to be accommo- 6109.2010.02127.x
dated when making recommendations in order to maximize 10. Cooperberg MR, Koppie TM, Lubeck DP, et al. How potent is potent? Evaluation of sexual function
applicability. Further work is required to define subsequent and bother in men who report potency after treatment for prostate cancer: Data from capsure. Urology
clinical management benchmarks, particularly in the context 2003;61:190-6. https://doi.org/10.1016/S0090-4295(02)02118-0
of RT. The development of an algorithm that incorporates 11. Penson DF, Latini DM, Lubeck DP, et al. Is quality of life different for men with erectile dysfunction and
prostate cancer compared to men with erectile dysfunction due to other causes? Results from the exceed
these many different facets should prove a novel and use- data base. J Urol 2003;169:1458-61. https://doi.org/10.1097/01.ju.0000054462.88306.43
ful tool for clinicians wishing to support patient’s erectile 12. Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate
recovery after PCa treatment. cancer. Eur Urol 2015;68:374-83. https://doi.org/10.1016/j.eururo.2015.04.023
13. Christopoulos D. Peer esteem snowballing: A methodology for expert surveys. Paper presented at: Eurostat
Competing interests: Dr. Elterman has been an advisory board and speakers’ bureau member conference for new techniques and technologies for statistics 2009.
for Allergan, Astellas, Boston Scientific, Duchesnay, Ferring, Medtronic, and Pfizer; has received 14. Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunc-
tion. Curr Urol Rep 2011;12:432-43. https://doi.org/10.1007/s11934-011-0216-y
grants/honoraria from Boston Scientific and Pfizer; and has participated in clinical trials supported 15. Salonia A, Burnett AL, Graefen M, et al. Prevention and management of post-prostatectomy sexual
by Astellas, Boston Scientific, and Medtronic. Dr. Walker has received unrestricted educational grants dysfunctions part 2: Recovery and preservation of erectile function, sexual desire, and orgasmic function.
from Abbvie and Astellas. Dr. Brock has been an advisory board member for Boston Scientific, Lilly, Eur Urol 2012;62:273-86. https://doi.org/10.1016/j.eururo.2012.04.047
and Paladin; a speakers’ bureau member for Astellas, Ferring, Lilly, and Pfizer; holds investments 16. Kirby MG, White ID, Butcher J, et al. Development of UK recommendations on treatment for post-surgical
in Lilly and Pfizer; and has participated in clinical trials supported by Astellas and Ferring. Dr. Finelli erectile dysfunction. Int J Clin Pract 2014;68:590-608. https://doi.org/10.1111/ijcp.12338
has been an advisory board member for Abbvie, Astellas, Bayer, Ipsen, Janssen, Sanofi, and TerSera; 17. Wittmann D, He C, Coelho M, et al. Patient preoperative expectations of urinary, bowel, hormonal and
and has participated in clinical trials supported by Astellas, Bayer, and Janssen. Dr. Gajewski has sexual functioning do not match actual outcomes 1 year after radical prostatectomy. J Urol 2011;186:494-
been an advisory board member for Astellas, Ferring, and Pfizer; and has received grants/honoraria 9. https://doi.org/10.1016/j.juro.2011.03.118
from Laborie, Medtronic, and Pfizer. Dr. Jarvi has been a consultant for Lilly; received a grant from 18. Bronner G, Shefi S, Raviv G. Sexual dysfunction after radical prostatectomy: Treatment failure or treat-
Allergan; and participated in a clinical trial supported by Allergan. Dr. Robinson has received grants ment delay? J Sex Marital Ther 2010;36:421-9. https://doi.org/10.1080/0092623X.2010.510777
from Abbvie and Astellas to support an ADT online program. The remaining authors report no 19. Boberg EW, Gustafson DH, Hawkins RP, et al. Assessing the unmet information, support, and care delivery
needs of men with prostate cancer. Patient Educ Couns 2003;49:233-42. https://doi.org/10.1016/
competing personal or financial interests related to this work. S0738-3991(02)00183-0
20. Vickers AJ, Kent M, Mulhall J, et al. Counselling the post-radical prostatectomy patients about functional
recovery: High predictiveness of current status. Urology 2014;84:158-63. https://doi.org/10.1016/j.
Funding: The consensus meeting was funded by a Prostate Cancer Canada Movember grant. urology.2014.02.049
21. Wittmann D, Montie JE, Hamstra DA, et al. Counselling patients about sexual health when considering
post-prostatectomy radiation treatment. Int J Impot Res 2009;21:275-84. https://doi.org/10.1038/
ijir.2009.32
This paper has been peer-reviewed. 22. Forbat L, White I, Marshall-Lucette S, et al. Discussing the sexual consequences of treatment in radio-
therapy and urology consultations with couples affected by prostate cancer. BJU Int 2012;109:98-103.
https://doi.org/10.1111/j.1464-410X.2011.10257.x
References 23. Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prosta-
tectomy. J Urol 2000;164:1929-34. https://doi.org/10.1016/S0022-5347(05)66921-2
24. Wittmann D, Carolan M, Given B, et al. Exploring the role of the partner in couples’ sexual recovery
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and after surgery for prostate cancer. Support Care Cancer 2014;22:2509-15. https://doi.org/10.1007/
major patterns in globocan 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210 s00520-014-2244-x
2. Canadian Cancer Society’s Steering Committee for Canadian Cancer Statistics. Canadian cancer statistics 25. Davison BJ, Keyes M, Elliott S, et al. Preferences for sexual information resources in patients treated for
2017. Toronto, ON: Canadian Cancer Society;2017. early-stage prostate cancer with either radical prostatectomy or brachytherapy. BJU Int 2004;93:965-9.
3. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with https://doi.org/10.1111/j.1464-410X.2003.04761.x
intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur 26. Lee DJ, Cheetham P, Badani KK. Penile rehabilitation protocol after robot-assisted radical prostatectomy:
Urol 2013;64:895-902. https://doi.org/10.1016/j.eururo.2013.03.033 Assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency.
4. Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A valid - BJU Int 2010;105:382-8. https://doi.org/10.1111/j.1464-410X.2009.08820.x
ated alternative to the Gleason score. Eur Urol 2016;69:428-35. https://doi.org/10.1016/j. 27. Buvat J, Buttner H, Hatzimouratidis K, et al. Adherence to initial pde-5 inhibitor treatment: Randomized
eururo.2015.06.046 open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients
with erectile dysfunction. J Sex Med 2013;10:1592-602. https://doi.org/10.1111/jsm.12130

244 CUAJ • August 2019 • Volume 13, Issue 8